Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study
Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV | Infectious Diseases and Therapy
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre
Full article: Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study
Switch studies - Etude ALIZE
JCM | Free Full-Text | Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV
INSIGHT: Wk 24 Efficacy, Safety, and PK of BIC/FTC/TAF in Adults With HIV and Tuberculosis Receiving Rifampicin | CCO
Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study
Gilead anuncia resultados de 96 semanas de estudo da fase 3 do BIKTARVY®
Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study,Infectious Diseases and Therapy - X-MOL